Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01398085 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

Study acronym: IoN
StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2024 to Mar 2031
    • Study sites: 32 to 36
    • Start date: May 2012 to Jun 26, 2012
    • Interventions: I131 1.1 GBq (Radiation) to I131 1.1 GBq (Radiation), No Radioactive iodine (No-RAI) ablation (Other)
    v17
  2. Primary completion date: Dec 2023 to Dec 2024v16
  3. 2 versions Re-verified since Jun 8, 2023, no change to tracked fieldsv14-v15
  4. Primary completion date: Mar 2023 to Dec 2023v13
  5. Re-verified, no change to tracked fieldsv12
Show 10 earlier versionsHide 10 earlier versions
  1. Primary completion date: Nov 2020 to Mar 2023v11 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 560 to confirmed 504
    • Study sites: 33 to 32
    • Study completion date: Jan 2021 to Mar 2031
  2. Eligibility criteria revisedv10
  3. Primary endpoints revised (2)v9 Show 4 more changesShow less
    • Enrollment target: 570 to 560
    • Eligibility criteria expanded, about 646 words
    • Secondary endpoints: 6 to 8
    • Site details revised at 8 of 33 sites
  4. Study sites: 31 to 33
    • Eligibility criteria expanded, about 149 words
    v8
  5. Re-verified, no change to tracked fieldsv7
  6. Study sites: 26 to 31v6
  7. Study sites: 24 to 26
    • Eligibility criteria expanded, about 38 words
    v5
  8. Eligibility criteria expanded, about 13 words
    • Study sites revised (24)
    v4
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Aug 2011 to May 2012
    • Study sites: 25 to 24
    • Eligibility criteria revised
    v3
  10. Secondary endpoints revised (6)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
IoN is a phase II/III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.
Trial Details
NCT Number NCT01398085
Lead Sponsor University College, London
Collaborators: Cancer Research UK
Conditions
(from sponsor)		 Thyroid Cancer, Thyroid Neoplasms
Related terms Adenocarcinoma, Follicular, Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms
Enrollment 504 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov